Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)‘s stock had its “buy” rating restated by investment analysts at Oppenheimer Holdings, Inc. in a research note issued to investors on Sunday. They currently have a $25.00 price objective on the biopharmaceutical company’s stock. Oppenheimer Holdings, Inc.’s price objective suggests a potential upside of 93.05% from the stock’s previous close.
Several other brokerages have also recently commented on VNDA. Zacks Investment Research cut Vanda Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, October 26th. Jefferies Group LLC reaffirmed a “buy” rating and issued a $21.00 target price on shares of Vanda Pharmaceuticals in a research report on Tuesday, August 29th. Piper Jaffray Companies set a $26.00 target price on Vanda Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, October 19th. ValuEngine lowered Vanda Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, October 26th. Finally, HC Wainwright set a $18.00 price objective on Vanda Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, August 3rd. One analyst has rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the company. Vanda Pharmaceuticals has an average rating of “Buy” and a consensus target price of $21.50.
Shares of Vanda Pharmaceuticals (VNDA) opened at $12.95 on Friday. Vanda Pharmaceuticals has a 12-month low of $11.90 and a 12-month high of $18.99.
Vanda Pharmaceuticals (NASDAQ:VNDA) last issued its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.10) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.10). The business had revenue of $41.30 million during the quarter, compared to analysts’ expectations of $43.90 million. Vanda Pharmaceuticals had a negative return on equity of 10.99% and a negative net margin of 9.01%. Vanda Pharmaceuticals’s revenue was up 7.3% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.01) earnings per share. equities research analysts predict that Vanda Pharmaceuticals will post -0.39 EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This report was published by TrueBlueTribune and is the sole property of of TrueBlueTribune. If you are reading this report on another domain, it was copied illegally and republished in violation of U.S. and international copyright legislation. The legal version of this report can be read at https://www.truebluetribune.com/2017/11/14/vanda-pharmaceuticals-inc-vnda-stock-rating-reaffirmed-by-oppenheimer-holdings-inc.html.
Large investors have recently made changes to their positions in the stock. Dynamic Technology Lab Private Ltd raised its holdings in shares of Vanda Pharmaceuticals by 46.3% during the second quarter. Dynamic Technology Lab Private Ltd now owns 20,510 shares of the biopharmaceutical company’s stock worth $335,000 after acquiring an additional 6,487 shares in the last quarter. Birchview Capital LP raised its holdings in shares of Vanda Pharmaceuticals by 25.9% during the second quarter. Birchview Capital LP now owns 68,000 shares of the biopharmaceutical company’s stock worth $1,108,000 after acquiring an additional 14,000 shares in the last quarter. State of Wisconsin Investment Board purchased a new stake in shares of Vanda Pharmaceuticals during the second quarter worth $538,000. American International Group Inc. raised its holdings in shares of Vanda Pharmaceuticals by 7.1% during the first quarter. American International Group Inc. now owns 22,563 shares of the biopharmaceutical company’s stock worth $316,000 after acquiring an additional 1,491 shares in the last quarter. Finally, AJO LP raised its holdings in shares of Vanda Pharmaceuticals by 94.2% during the second quarter. AJO LP now owns 541,927 shares of the biopharmaceutical company’s stock worth $8,833,000 after acquiring an additional 262,833 shares in the last quarter. Institutional investors and hedge funds own 87.28% of the company’s stock.
About Vanda Pharmaceuticals
Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).
Receive News & Ratings for Vanda Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.